We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NUTX Q3 Earnings Call Highlights Reimbursement and Hospital Growth
Read MoreHide Full Article
Key Takeaways
Nutex Health's Q3 revenues fell 18.7% to $217.6M, while hospital visits rose 18.1% to 54,622.
NUTX won over 80% of arbitration determinations in 9 months, with revenue per visit stabilizing near $4,000.
Nutex Health plans two hospital openings in Q4 2026, backed by $249.9M in cash and a focus on expansion.
Nutex Health Inc. (NUTX - Free Report) emphasized improving hospital volumes, stable collections and disciplined expansion during its third-quarter 2026 earnings call, even as year-over-year revenues declined.
Management highlighted reimbursement developments, arbitration costs and hospital openings as key considerations for future performance. Executives also addressed revenue-per-visit trends, capital allocation and potential regulatory changes during the analyst discussion.
Nutex Addresses Revenue and Reimbursement Trends
Chief financial officer Jon Bates attributed the revenue decline primarily to favorable collection-estimate adjustments that inflated the comparable 2025 period. Third-quarter revenues declined 18.7% to $217.6 million.
Earnings per share of $5.71 exceeded the Zacks Consensus Estimate of $5.53. Revenues also surpassed the $216.9 million consensus estimate.
Nutex Health Inc. Price, Consensus and EPS Surprise
Bates explained that revenue per visit has stabilized near $4,000 during 2026, compared with approximately $5,600 in third-quarter 2025. Management expects the metric to remain within its recent range if collection assumptions remain stable.
NUTX Maintains Strong Arbitration Collections
Chairman and chief executive officer Thomas Vo emphasized continued collection strength under the No Surprises Act's independent dispute resolution process.
Approximately 50-60% of billable visits enter arbitration, while 40-50% result in award determinations. Nutex prevailed in more than 80% of determinations over the past nine months and collected more than 80% of award amounts on average for the specified historical awards.
During analyst questioning, Bates acknowledged slightly weaker physician-side collections, although hospital reimbursements remained stable. Management continues monitoring this divergence without identifying a material underlying cause.
Nutex Sees Patient Demand Supporting Growth
Chief operating officer Wesley Bamburg highlighted accelerating patient volumes, supported by expanded clinical capabilities and coordinated business development.
Third-quarter hospital visits increased 18.1% to 54,622, while same-hospital visits rose 12.4%. Management attributed the improvement to localized marketing, physician engagement and broader diagnostic and specialty services.
During the Lake Street Capital Markets discussion, Bamburg emphasized systematically sharing successful business development practices across facilities. Investments in imaging, automation and artificial intelligence remain focused on improving clinical efficiency and expanding patient services.
NUTX Monitors Regulatory and Arbitration Changes
Vo highlighted favorable federal court rulings concerning arbitration award enforcement and qualifying payment calculations. Management views these developments as supportive of fairer reimbursement practices.
The company supports the proposed Murphy legislation, which would strengthen arbitration enforcement, while opposing the Pallone proposal that would eliminate the federal IDR process beginning in 2028.
Responding to B. Riley Securities, Vo acknowledged uncertainty surrounding legislative outcomes. Bates also noted that reduced administrative fees and improvements to the federal arbitration portal could streamline disputes, although procedural delays remain challenging.
Nutex Prioritizes Hospital Expansion and Cash Deployment
Management expects two hospitals, located in San Antonio and Jacksonville, to open during fourth-quarter 2026. Four additional facilities under construction are targeted for late 2027 or early 2028.
During the StoneX discussion, Bates identified hospital development as management's preferred use of capital. The company held $249.9 million in cash at September-end, supporting expansion and infrastructure investments.
Vo reiterated an external growth target of three to five hospitals annually. Share repurchases, dividends and alternative investments remain under board consideration, with growth retaining priority.
NUTX Expands Its Physician Network Strategy
President Warren Hosseinion outlined plans to establish one or two independent physician associations annually around existing hospitals.
The population health division manages nearly 40,000 members. Planned patient enrollment in Dallas and San Antonio during 2027 will complement existing physician networks.
During the Lake Street discussion, Hosseinion emphasized that these networks are intended to improve referrals, care coordination and hospital utilization rather than maximize membership.
Nutex Maintains Its Operational Priorities
Management's overall tone remained constructive but measured, emphasizing patient growth, consistent reimbursement and disciplined spending.
Executives remain focused on converting stronger hospital utilization into sustainable financial performance while navigating reimbursement uncertainty and executing planned facility openings.
NUTX Zacks Rank and Style Scores Signal Mixed Prospects
NUTX currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term outlook. Its Value Score of A, Growth Score of A and VGM Score of A reflect favorable valuation and growth characteristics, while its Momentum Score of D indicates weaker price momentum. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The combination presents mixed signals because strong fundamental Style Scores coexist with a neutral Zacks Rank and weak momentum. The Zacks Rank may change as analysts revise earnings estimates following the latest quarterly results.
View the Zacks #1 Rank List
Image: Bigstock
NUTX Q3 Earnings Call Highlights Reimbursement and Hospital Growth
Key Takeaways
Nutex Health Inc. (NUTX - Free Report) emphasized improving hospital volumes, stable collections and disciplined expansion during its third-quarter 2026 earnings call, even as year-over-year revenues declined.
Management highlighted reimbursement developments, arbitration costs and hospital openings as key considerations for future performance. Executives also addressed revenue-per-visit trends, capital allocation and potential regulatory changes during the analyst discussion.
Nutex Addresses Revenue and Reimbursement Trends
Chief financial officer Jon Bates attributed the revenue decline primarily to favorable collection-estimate adjustments that inflated the comparable 2025 period. Third-quarter revenues declined 18.7% to $217.6 million.
Earnings per share of $5.71 exceeded the Zacks Consensus Estimate of $5.53. Revenues also surpassed the $216.9 million consensus estimate.
Nutex Health Inc. Price, Consensus and EPS Surprise
Nutex Health Inc. price-consensus-eps-surprise-chart | Nutex Health Inc. Quote
Bates explained that revenue per visit has stabilized near $4,000 during 2026, compared with approximately $5,600 in third-quarter 2025. Management expects the metric to remain within its recent range if collection assumptions remain stable.
NUTX Maintains Strong Arbitration Collections
Chairman and chief executive officer Thomas Vo emphasized continued collection strength under the No Surprises Act's independent dispute resolution process.
Approximately 50-60% of billable visits enter arbitration, while 40-50% result in award determinations. Nutex prevailed in more than 80% of determinations over the past nine months and collected more than 80% of award amounts on average for the specified historical awards.
During analyst questioning, Bates acknowledged slightly weaker physician-side collections, although hospital reimbursements remained stable. Management continues monitoring this divergence without identifying a material underlying cause.
Nutex Sees Patient Demand Supporting Growth
Chief operating officer Wesley Bamburg highlighted accelerating patient volumes, supported by expanded clinical capabilities and coordinated business development.
Third-quarter hospital visits increased 18.1% to 54,622, while same-hospital visits rose 12.4%. Management attributed the improvement to localized marketing, physician engagement and broader diagnostic and specialty services.
During the Lake Street Capital Markets discussion, Bamburg emphasized systematically sharing successful business development practices across facilities. Investments in imaging, automation and artificial intelligence remain focused on improving clinical efficiency and expanding patient services.
NUTX Monitors Regulatory and Arbitration Changes
Vo highlighted favorable federal court rulings concerning arbitration award enforcement and qualifying payment calculations. Management views these developments as supportive of fairer reimbursement practices.
The company supports the proposed Murphy legislation, which would strengthen arbitration enforcement, while opposing the Pallone proposal that would eliminate the federal IDR process beginning in 2028.
Responding to B. Riley Securities, Vo acknowledged uncertainty surrounding legislative outcomes. Bates also noted that reduced administrative fees and improvements to the federal arbitration portal could streamline disputes, although procedural delays remain challenging.
Nutex Prioritizes Hospital Expansion and Cash Deployment
Management expects two hospitals, located in San Antonio and Jacksonville, to open during fourth-quarter 2026. Four additional facilities under construction are targeted for late 2027 or early 2028.
During the StoneX discussion, Bates identified hospital development as management's preferred use of capital. The company held $249.9 million in cash at September-end, supporting expansion and infrastructure investments.
Vo reiterated an external growth target of three to five hospitals annually. Share repurchases, dividends and alternative investments remain under board consideration, with growth retaining priority.
NUTX Expands Its Physician Network Strategy
President Warren Hosseinion outlined plans to establish one or two independent physician associations annually around existing hospitals.
The population health division manages nearly 40,000 members. Planned patient enrollment in Dallas and San Antonio during 2027 will complement existing physician networks.
During the Lake Street discussion, Hosseinion emphasized that these networks are intended to improve referrals, care coordination and hospital utilization rather than maximize membership.
Nutex Maintains Its Operational Priorities
Management's overall tone remained constructive but measured, emphasizing patient growth, consistent reimbursement and disciplined spending.
Executives remain focused on converting stronger hospital utilization into sustainable financial performance while navigating reimbursement uncertainty and executing planned facility openings.
NUTX Zacks Rank and Style Scores Signal Mixed Prospects
NUTX currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term outlook. Its Value Score of A, Growth Score of A and VGM Score of A reflect favorable valuation and growth characteristics, while its Momentum Score of D indicates weaker price momentum. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The combination presents mixed signals because strong fundamental Style Scores coexist with a neutral Zacks Rank and weak momentum. The Zacks Rank may change as analysts revise earnings estimates following the latest quarterly results.